Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
Robert P. Lyon(Seagen (United States)), Peter D. Senter(Seagen (United States)), Mechthild Jonas(Seagen (United States)), Martha E. Anderson(Seagen (United States)), Tim D. Bovee(Seagen (United States)), Haley D. Neff‐LaFord(Seagen (United States)), Svetlana O. Doronina(Seagen (United States)), Patrick Burke(Seagen (United States)), Joshua H. Hunter(Seagen (United States)), Jocelyn R. Setter(Seagen (United States))
Cited by 521
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772